申请人:SUZHOU SINOVENT PHARMACEUTICALS CO., LTD.
公开号:US10821104B2
公开(公告)日:2020-11-03
A five-membered heterocyclic amide WNT pathway inhibitor having the following general structural formula:
The five-membered heterocyclic amide WNT pathway inhibitor has a remarkable anti-tumor activity based on a target-based rational drug design, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.
具有以下结构通式的五元杂环酰胺类 WNT 通路抑制剂:
该五元杂环酰胺类 WNT 通路抑制剂基于靶点合理药物设计,具有显著的抗肿瘤活性,可用于开发新一代 Wnt 通路抑制剂,具有极大的临床应用价值和可观的市场潜力。